Researchers recreated the damage seen in frontotemporal dementia in brain organoid models. The study reveals an experimental drug designed to treat Crohn's disease may help prevent neuron death associated with FTD.
Researchers report Alzheimer's disease and other neurodegenerative disorders can be confirmed in living patients by specific biomarkers in cerebrospinal fluid.
Study links anhedonia, or the loss of pleasure, to the early onset of frontotemporal dementia. Neuroimaging revealed symptoms of anhedonia were marked by atrophy in the frontal and striatal brain areas of those with FTD.
Study reveals those with frontotemporal dementia have greater white matter hyperintensity than those with other forms of dementia. The amount of white matter hyperintensity was associated with the severity of FTD symptoms.
c9ASO, an investigational ASO drug, targets the TDP-43 protein, reducing its buildup and decreasing neurological decline associated with ALS and FTD.
Study reveals why some people with ALS are prone to developing autoimmune diseases. A genetic mutation that decreases the expression of C9orf72 causes the stimulation of interferon genes (STING) protein to become hyperactive. The hyperactivity leads to increased production of interferons. This can lead to systemic inflammation and the development of autoimmune diseases.
Researchers have identified how specific genetic mutations cause ALS. The pathway, they believe, may also be responsible for the development of frontotemporal dementia.
In all three types of frontotemporal dementia, researchers found the more the inflammation in each part of the brain, the more harmful the build-up of junk proteins.
The protein beta-arrestin-2 increases tau tangle accumulation in Alzheimer's disease and frontotemporal dementia but interfering with the removal of excess tau from the brain.
Gentamicin and G418, two aminoglycoside antibiotics, were effective at correcting genetic mutations associated with a specific form of frontotemporal dementia. The findings are promising for the treatment of frontotemporal dementia.
Those with a genetic predisposition to frontotemporal dementia (FTD) can become resilient to the neurodegenerative disease by remaining physically and mentally active.
Reducing activity in the anterior cingulate decreases empathetic responses in rats. The data suggests an observer shares the emotions of others as it enables them to prepare for danger.
